Frequently Asked Questions
The market is segmented based on Global Parkinson’s Disease Market By Drug Class (Levodopa/Carbidopa, Dopamine Receptor Agonists, MAO-Inhibitors, COMT-Inhibitors, Anticholinergics, Other Drugs), Medical Devices (Deep Brain Stimulation (DBS) Devices, Carbidopa/Levodopa Enteral Suspension (Duopa) Delivery Devices), Route of Administration (Oral, Transdermal, Subcutaneous, Intestinal Infusion, Others), Distribution Channel (Hospital Pharmacies, Clinics, Retail Pharmacies, Online Pharmacies), Patient Care Setting (Hospitals, Clinics) - Industry Trends and Forecast to 2030.
.
The Global Parkinsons Disease Market size was valued at USD 2.80 USD Billion in 2022.
The Global Parkinsons Disease Market is projected to grow at a CAGR of 9.2% during the forecast period of 2023 to 2023.
The major players operating in the market include GlaxoSmithKline plc, Teva Pharmaceutical Industries , Boehringer Ingelheim International GmbH, Impax Laboratories LLC, AbbVie , Bausch Health, Lundbeck, Sun Pharmaceutical Industries , ACADIA Pharmaceuticals , Merck & Co. , Novartis AG, UCB S.A., Dr. Reddy's Laboratories , WOCKHARDT, La Roche Ltd, STADA Arzneimittel AG, Orion Corporation, Mylan N.V, Cipla , Par Pharmaceutical, DAIICHI SANKYO COMPANY LIMITED, Apotex .
The market report covers data from the U.S., Canada, Mexico, Brazil, Argentina, Peru, Rest of South America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Saudi Arabia, U.A.E, Egypt, Israel, Kuwait, South Africa, Rest of Middle East and Africa.
